Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells

Brain Research

Volumn 1302, Issue , 2009, Pages 21-33

  Qian, Yongchang ^a   Zheng, Ying ^a   Tiffany Castiglioni, Evelyn ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Neurite Outgrowth; Neuroblastoma cell; NF160; Reversal; Valproate

Indexed keywords

MESSENGER RNA; NERVE GROWTH FACTOR; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN 160; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; ARTICLE; ASTROCYTOMA CELL; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; NERVE FIBER GROWTH; NEUROBLASTOMA CELL; NEUROFILAMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIMANIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; NERVE GROWTH FACTOR; NEURITES; NEUROBLASTOMA; NEUROFILAMENT PROTEINS; PARKINSONIAN DISORDERS; PC12 CELLS; RATS; RNA, MESSENGER; SUBSTANTIA NIGRA; VALPROIC ACID;

RATTUS;

EID: 71949097073     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.09.051     Document Type: Article

References (45)

1. Adab N., Kini U., Vinten J., Ayres J., Baker G., Clayton-Smith J., Coyle H., Fryer A., Gorry J., Gregg J., Mawer G., Nicolaides P., Pickering L., Tunnicliffe L., and Chadwick D.W. The longer term outcome of children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1575-1583
2. Aguirre G., Rosas S., Lopez-Bayghen E., and Ortega A. Valproate-dependent transcriptional regulation of GLAST/EAAT1 expression: involvement of Ying-Yang 1. Neurochem. Int. 52 (2008) 1322-1331
3. Al-Chalabi A., and Miller C.C. Neurofilaments and neurological disease. Bioessays 25 (2003) 346-355
4. Alvarez-Gomez M.J., Vaamonde J., Narbona J., Barao M., Barona P., Brannan T., Gudin M., and Ibanez R. Parkinsonian syndrome in childhood after sodium valproate administration. Clin. Neuropharmacol. 16 (1993) 451-455
5. Armon C., Shin C., Miller P., Carwile S., Brown E., Edinger J.D., and Paul R.G. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 47 (1996) 626-635
6. Bahat-Stroomza M., Barhum Y., Levy Y.S., Karpov O., Bulvik S., Melamed E., and Offen D. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. J. Mol. Neurosci. 39 (2009) 199-210
7. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., Rosenthal A., and Hefti F. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 (1995) 339-341
8. Bialer M. Clinical pharmacology of valpromide. Clin. Pharmacokinet 20 (1991) 114-122
9. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., Small J.G., et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Jama 271 (1994) 918-924
10. Bown C.D., Wang J.F., and Young L.T. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology 39 (2000) 2162-2169
11. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., Wilson B., Lu R.B., Gean P.W., Chuang D.M., and Hong J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11 (2006) 1116-1125
12. Cho T., and Tiffany-Castiglioni E. Neurofilament 200 as an indicator of differences between mipafox and paraoxon sensitivity in Sy5Y neuroblastoma cells. J. Toxicol. Environ. Health A 67 (2004) 987-1000
13. Cunningham L.A., and Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp. Neurol. 174 (2002) 230-242
14. Cunningham L.A., Short M.P., Breakefield X.O., and Bohn M.C. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. Brain Res. 658 (1994) 219-231
15. Di Daniel E., Mudge A.W., and Maycox P.R. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord. 7 (2005) 33-41
16. Dou H., Birusingh K., Faraci J., Gorantla S., Poluektova L.Y., Maggirwar S.B., Dewhurst S., Gelbard H.A., and Gendelman H.E. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J. Neurosci. 23 (2003) 9162-9170
17. Easterford K., Clough P., Kellett M., Fallon K., and Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 62 (2004) 1435-1437
18. Encinas M., Iglesias M., Llecha N., and Comella J.X. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J. Neurochem. 73 (1999) 1409-1421
19. Gaily E., Kantola-Sorsa E., Hiilesmaa V., Isoaho M., Matila R., Kotila M., Nylund T., Bardy A., Kaaja E., and Granstrom M.L. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62 (2004) 28-32
20. Goldman J.E., Yen S.H., Chiu F.C., and Peress N.S. Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 221 (1983) 1082-1084
21. Gomez-Santos C., Ferrer I., Reiriz J., Vinals F., Barrachina M., and Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 935 (2002) 32-39
22. Guerrini R., Belmonte A., Canapicchi R., Casalini C., and Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 39 (1998) 27-32
23. Hao Y., Creson T., Zhang L., Li P., Du F., Yuan P., Gould T.D., Manji H.K., and Chen G. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24 (2004) 6590-6599
24. Hasegawa T., Matsuzaki M., Takeda A., Kikuchi A., Furukawa K., Shibahara S., and Itoyama Y. Increased dopamine and its metabolites in SH-SY5Y neuroblastoma cells that express tyrosinase. J. Neurochem. 87 (2003) 470-475
25. Hong M.S., Hong S.J., Barhoumi R., Burghardt R.C., Donnelly K.C., Wild J.R., Venkatraj V., and Tiffany-Castiglioni E. Neurotoxicity induced in differentiated SK-N-SH-SY5Y human neuroblastoma cells by organophosphorus compounds. Toxicol. Appl. Pharmacol. 186 (2003) 110-118
26. Kirik D., Winkler C., and Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 21 (2001) 2889-2896
27. Laeng P., Pi`tts R.L., Lemire A.L., Drabik C.E., Weiner A., Tang H., Thyagarajan R., Mallon B.S., and Altar C.A. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J. Neurochem. 91 (2004) 238-251
28. Lai J.S., Zhao C., Warsh J.J., and Li P.P. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur. J. Pharmacol. 539 (2006) 18-26
29. Lavedan C., Buchholtz S., Nussbaum R.L., Albin R.L., and Polymeropoulos M.H. A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci. Lett. 322 (2002) 57-61
30. Lee M.K., and Cleveland D.W. Neuronal intermediate filaments. Annu. Rev. Neurosci. 19 (1996) 187-217
31. Lindenbaum M.H., Carbonetto S., and Mushynski W.E. Nerve growth factor enhances the synthesis, phosphorylation, and metabolic stability of neurofilament proteins in PC12 cells. J. Biol. Chem. 262 (1987) 605-610
32. Lindenbaum M.H., Carbonetto S., Grosveld F., Flavell D., and Mushynski W.E. Transcriptional and post-transcriptional effects of nerve growth factor on expression of the three neurofilament subunits in PC-12 cells. J. Biol. Chem. 263 (1988) 5662-5667
33. Masmoudi K., Gras-Champel V., Masson H., and Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 39 (2006) 9-12
34. Onofrj M., Thomas A., and Paci C. Reversible parkinsonism induced by prolonged treatment with valproate. J. Neurol. 245 (1998) 794-796
35. Papazian O., Canizales E., Alfonso I., Archila R., Duchowny M., and Aicardi J. Reversible dementia and apparent brain atrophy during valproate therapy. Ann. Neurol. 38 (1995) 687-691
36. Pope Jr. H.G., McElroy S.L., Keck Jr. P.E., and Hudson J.I. Valproate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psychiatry 48 (1991) 62-68
37. Qian Y.C., Tiffany-Castiglioni E., and Harris E.D. A Menkes P-type ATPase involved in copper homeostasis in the central nervous system of the rat. Brain Res. Mol. Brain Res. 48 (1997) 60-66
38. Qian Y.C., Harris E.D., Zheng Y., and Tiffany-Castiglioni E. Lead targets GRP78, a molecular chaperone, in C6 rat glioma cells. Toxicol. Appl. Pharmacol. 163 (2000) 260-266
39. Qian Y.C., Zheng Y., Abraham L., Ramos K.S., and Tiffany-Castiglioni E. Differential profiles of copper-induced ROS generation in human neuroblastoma and astrocytoma cells. Brain Res. Mol. Brain Res. 134 (2005) 323-332
40. Ristic A.J., Vojvodic N., Jankovic S., Sindelic A., and Sokic D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 47 (2006) 2183-2185
41. Sasso E., Delsoldato S., Negrotti A., and Mancia D. Reversible valproate-induced extrapyramidal disorders. Epilepsia 35 (1994) 391-393
42. Satoh T., Furuta K., Tomokiyo K., Nakatsuka D., Tanikawa M., Nakanishi M., Miura M., Tanaka S., Koike T., Hatanaka H., Ikuta K., Suzuki M., and Watanabe Y. Facilitatory roles of novel compounds designed from cyclopentenone prostaglandins on neurite outgrowth-promoting activities of nerve growth factor. J. Neurochem. 75 (2000) 1092-1102
43. Sechi G.P., Conti M., Sau G.F., and Cocco G.A. Valproate-induced parkinsonism, glial cells and Alexander's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1351-1352
44. Williams R.S., Cheng L., Mudge A.W., and Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 417 (2002) 292-295
45. Zaret B.S., and Cohen R.A. Reversible valproic acid-induced dementia: a case report. Epilepsia 27 (1986) 234-240